Early Diagnostics ActivSignal's BlueSCAI platform offers ultrahigh sensitivity with attomolar detection and a five log advantage in limit of detection, enabling early cancer biomarker panels such as PanDx to be read from tiny samples. The combination of background removal, high specificity, and scalable multiplexing supports development of early detection diagnostics across oncology and translational research. This creates a compelling entry point for pilot collaborations with cancer centers, academic labs, and translational institutes seeking to validate low abundance biomarkers.

CRO Partnerships BlueSCAI enables multiplex profiling of hundreds of biomarkers from the same small sample with high specificity and low input requirements, making it attractive for CROs and contract research labs delivering multiplex proteomics services. Its MPAD technology supports scalable panels from single to large biomarker sets, offering potential for white-labeling or joint service offerings that help CROs expand their assay menus and win biomarker discovery contracts.

Pharma Collaboration Mechanistic biology mapping capabilities allow time-resolved pathway responses to stimuli, drugs, and stressors to be profiled at high plex with NGS read out, aligning with pharma R&D needs for mechanism of action and pharmacodynamics studies. This positions ActivSignal as a collaborator for drug development programs, enabling deeper biomarker insight during preclinical and early clinical work.

Licensing Opportunities Technology licensing and partnership opportunities exist to integrate MPAD with larger diagnostics or sequencing platforms. The unique dual-antibody proximity detection with NGS read out offers a path for co-development or exclusive licensing, enabling partners to add ultra-sensitive multiplex protein profiling to their workflows without building new platforms from scratch.

Growth and Funding ActivSignal has demonstrated early market traction with Stage 1 funding and mid-market revenue, and a small team, suggesting leveraging regional and national channel partnerships. The Natick, MA base supports outreach to Northeast biotech clusters and academic networks. Opportunities include grant-funded pilots, university collaborations, and strategic partnerships that accelerate adoption of BlueSCAI in oncology biomarker discovery and early detection programs.